STAT Plus: ‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation
CAMBRIDGE, Mass. — Biopharma’s reputation is, objectively speaking, the worst.
And on Thursday, several biotech CEOs said in no uncertain terms that they believed that negative reputation was earned — particularly because of some drug pricing decisions.
